Ampio enrolling patients for inhalable COVID-19 Phase I trial

By Jenni Spinner

- Last updated on GMT

(Dr. Microbe/iStock via Getty Images Plus)
(Dr. Microbe/iStock via Getty Images Plus)

Related tags COVID-19 Coronavirus phase I Clinical trial inhalation products Lung

The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment.

Ampio Pharmaceuticals, a company specializing in immunology-based therapies for inflammatory conditions, has announced that its ongoing Phase I clinical trial in the US, exploring inhalation treatment of COVID-19 with Ampion (AP-014), is now 55% enrolled. The trial is looking at the impact of inhaled Ampion treatments in patients suffering respiratory distress as a result of COVID-19 infection.

Inhaled Ampion specifically targets inflammation in the lung. Researchers are hopeful that the use of the drug stands to improve the clinical outcome for patients with respiratory distress due to COVID-19.

To date, according to Ampio CEO Mike Macaluso, researchers are hopeful about Ampion’s promise to treat patients dealing with the virus.

We've received amazing feedback from healthcare providers about the improvement seen in patients receiving inhaled Ampion​," Macaluso said. “We continue to remain very optimistic at the early, anecdotal evidence regarding the clinical effectiveness of inhaled Ampion in COVID-19 patients, and eagerly await the full results of this trial​."

Michael Roshon, chief of medical staff for Penrose-St. Francis Health Services, said, “Our experience using inhaled Ampion to treat patients with COVID-19 continues to trend positively showing no serious drug-related adverse effects. We look forward to seeing the full results of the study as therapeutics for COVID-19 continue to be in high demand​.”

As of early 2021, more than 22m Americans have been diagnosed with COVID-19; this figure comprises nearly 25% of the total cases around the world (the US is home to 4% of the world's population). While vaccines are increasingly available, pharmaceutical firms and their research partners remain hard at work in the pursuit of therapies to treat COVID-19 patients, including those suffering from most challenging and damaging effects (such as systemic inflammation in the lungs).

Researchers report that so far, the study of inhaled Ampion in COVID-19 patients has exhibited no drug-related serious adverse events (SAE). The company reportedly anticipates feedback from the Safety Monitoring Committee (SMC), analyzing any safety concerns related to inhaled Ampion, to come through later this month.

Ampion in vitro interrupts the hyper-active immune response, known as cytokine storm, that is directly associated with the more serious symptoms of COVID-19. The benefit of this effect from Ampion is currently being studied in multiple human clinical trials.

Along with the US-based trial of Ampion, Ampio Pharmaceuticals reports it has initiated a global study in Israel and the US for patients with moderate to severe COVID-19. This trial is centered on assessment of the safety and efficacy of intravenous Ampion treatment in both a hospital setting and as a therapy for out-patient care.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more